Pyoderma gangrenosum (PG) is a severe extraintestinal manifestation of inflammatory bowel disease (IBD).
Objective
To better characterize PG features and management among an IBD cohort.
Methods
Subjects with PG were identified using a large database at a tertiary center. Patient demographics and clinical characteristics were summarized using descriptive statistics.
Results
Eighty patients with an episode(s) of PG were identified, yielding an overall prevalence of 1.9%. Overall, 93% of patients with PG had some degree of colonic inflammation. Thirty-one (39%) patients required hospitalization for PG. Underlying bowel disease was active at the time of PG episode(s) in 52 (65%) patients. The PG location was variable, with the lower extremity being the most common. Most patients (71.3%) required multiple therapies to achieve PG healing.
Conclusions
We describe one of the largest case series of PG among patients with IBD. The variety of treatment strategies used highlights the lack of clear guidelines in managing this complex group of patients.
MarzanoAV, CugnoM, TrevisanV.Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophilmediated skin diseases.Clin Exp Immunol2010; 162: 100–7, doi:10.1111/j.1365-2249.2010.04201.x.
4.
MarzanoAV, BorghiA, StadnickiA.Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy.Inflamm Bowel Dis2014; 20: 213–27, doi:10.1097/01.MIB.0000436959.62286.f9.
5.
PowellFC, SuWP, PerryHO.Pyoderma gangrenosum: classification and management.J Am Acad Dermatol1996; 34: 395–409, doi:10.1016/S0190-9622(96)90428-4.
6.
ThorntonJR, TeagueRH, Low-BeerTS.Pyoderma gangrenosum and ulcerative colitis.Gut1980; 21: 247, doi:10.1136/gut.21.3.247.
7.
AgarwalA, AndrewsJM.Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.Aliment Pharmacol Ther2013; 38: 563–72, doi:10.1111/apt.12431.
8.
LindgrenA, WallerstedtS, OlssonR.Prevalence of Crohn's disease and simultaneous occurrence of extra-intestinal complications and cancer. An epidemiologic study in adults.Scand J Gastroenterol1996; 31: 74–8, doi:10.3109/00365529609031630.
9.
GreensteinAJ, JanowitzHD, SacharDB.The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients.Medicine (Baltimore)1976; 55: 401–12, doi:10.1097/00005792-197609000-00004.
10.
BernsteinCN, BlanchardJF, RawsthorneP.The prevalence of extra-intestinal manifestations in inflammatory bowel disease: a population based study.Am J Gastroenterol2001; 96: 1116–22, doi:10.1111/j.1572-0241.2001.03756.x.
11.
Mir-MadjlessiSH, TaylorJS, FarmerRG.Clinical course and evaluation of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients.Am J Gastroenterol1985; 80: 615–20.
RegueiroM, ValentineJ, PlevyS.Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.Am J Gastroenterol2003; 98: 1821.
14.
SilverbergMS, SatsangiJ, AhmadT.Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.Can J Gastroenterol2005; 19 Suppl A: 5–36.
15.
HadiA, LebowhlM.Clinical features of pyoderma gangrenosum and current diagnostic trends.J Am Acad Dermatol2011; 64: 950–4, doi:10.1016/j.jaad.2010.01.049.
16.
VavrickaSR, BrunL, BallabeniP.Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.Am J Gastroenterol2011; 196: 110–9, doi:10.1038/ajg.2010.343.
17.
PolczM, GuJ, FlorinT.Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services Adult Hospital 1998-2009.J Crohns Colitis2011; 5: 148–51, doi:10.1016/j.crohns.2010.10.006.
18.
MonsenU, SorstadJ, HellersG.Extracolonic diagnoses in ulcerative colitis: an epidemiological study.Am J Gastroenterol1990; 85: 711–6.
19.
BhagatS, DasKM.A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody.Gastroenterology1994; 107: 103–8.
20.
VasiliauskasEA, PlevySE, LandersCJ.Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.Gastroenterology1996; 110: 1810–9, doi:10.1053/gast.1996.v110.pm8964407.
21.
GordonLK, EggenaM, HollandGN.pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.J Clin Immunol1998; 18: 264–71, doi:10.1023/A:1027333822801.
22.
StokkersPC, ReitsmaPH, TytgatGN.HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis.Gut1999; 45: 395–401, doi:10.1136/gut.45.3.395.
23.
FreemanHJ.Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease.Can J Gastroenterol2005; 19: 603–6.
24.
von den DrieschP.Pyoderma gangrenosum: a report of 44 cases with follow up.Br J Dermatol1997; 137: 1000–5, doi:10.1046/j.1365-2133.1997.20022083.x.
25.
BinusAM, QureshiAA, LiVW.Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities, and therapy in 103 patients.Br J Dermatol2011; 165: 1244–50, doi:10.1111/j.1365-2133.2011.10565.x.
26.
SaracinoA, KellyR, LiewD.Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up.Australas J Dermatol2011; 52: 218–21, doi:10.1111/j.1440-0960.2011.00750.x.
27.
VidalD, PuigL, GilaberteM.Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features.J Dermatolog Treat2004; 15: 146–52, doi:10.1080/09546630410031909.
MarzanoAV, TrevisanV, LazzariR.Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic’ classification.J Dermatolog Treat2011; 22: 254–60, doi:10.3109/09546631003686069.
30.
ReichrathJ, BensG, BonowitzA.Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.J Am Acad Dermatol2005; 53: 273–83, doi:10.1016/j.jaad.2004.10.006.
31.
ChowRKP, HoVC.Treatment of pyoderma gangrenosum.J Am Acad Dermatol1996; 34: 1047–60, doi:10.1016/S0190-9622(96)90285-6.
32.
BrooklynTN, DunnillMG, ShettyA.Infliximab for the treatment of pyoderma gangrenosum: a randomized double blind, placebo controlled trial.Gut2006; 55: 505–9, doi:10.1136/gut.2005.074815.
33.
DenadaiR, TeixeiraFV, SteinwurzF.Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.J Crohns Colitis2013; 7: 517–24, doi:10.1016/j.crohns.2012.08.007.
34.
MarzanoAV, BorghiA, MeroniPL.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Autoimmunity2014 Jan 20. [Epub ahead of print]
35.
MedkourF, BabaiS, ChanteloupE.Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab.Gastroenterol Clin Biol2010; 34: 140–1, doi:10.1016/j.gcb.2009.10.021.
